Pieris Pharmaceuticals Culture Company

Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder served as Chief Executive Officer of Pieris Operating from January 04, 2010 to December 17, 2014. From July 2003 to December 2010 he led the intellectual property and legal departments at MorphoSys AG, a biotechnology company involved in the development and research of antibodies, as General Counsel. From September 1999 to June 2003 he worked in several Washington, D.C. law firms, specializing in a life sciences intellectual property practice. He has been a Director of Pieris Pharmaceuticals, Inc. since December 17,2014. Mr. Yoder holds degrees in molecular biology and Spanish from Grove City College and a Juris Doctorate, with honors, from The George Washington University Law School.

Dr. Louis A. Matis, M.D., Ph.D., has been the Chief Development Officer and Senior Vice President at Pieris Pharmaceuticals, Inc. since August 17,2015. Dr. Matis served as Chief Executive Officer and President of The Immune Tolerance Institute Inc., from 2007 to 2010. Dr. Matis served as Chief Executive Officer of CGI Pharmaceuticals, Inc. since June 2001, its President and Chief Scientific Officer from September 2000 to 2006. Dr. Matis has more than twenty-five years of extensive, broad-based experience encompassing basic and clinical research, clinical medicine, regulatory affairs and the biotechnology industry. Dr. Matis joined CGI Pharmaceuticals in September 2000. Dr. Matis is an internationally recognized immunologist whose work has been published in such prestigious journals as Nature, Science, Cell, Proceedings of the National Academy of Sciences USA, the Journal of Experimental Medicine, Nature Medicine, the Journal of Immunology and the Journal of Clinical Investigation, Dr. Matis has extensive experience translating groundbreaking biomedical research into novel clinical therapies. Prior to joining Cellular Genomics, Dr. Matis served as Senior Vice President and Chief Scientific Officer of Alexion Pharmaceuticals, where he played a seminal role in the discovery and development of novel biopharmaceuticals now in late stage clinical trials. Dr. Matis remains a member of the Scientific Advisory Board of Alexion Pharmaceuticals. Dr. Matis served since June 2011 as Executive Director, Strategic Evaluation at Alexion Pharmaceuticals, where he also served from 1993 to 2000, during which time he advanced to the position of Chief Scientific Officer and had a leading role in discovering the first-in-class complement inhibitor monoclonal antibody Soliris (eculizumab). Before joining Alexion Pharmaceuticals in 1993, Dr. Matis held various appointments at the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research from 1977 to 1992. He served as Senior Investigator in the Laboratory of Immunoregulation and attending physician in the Medicine Branch of the National Cancer Institute from 1990 to 1992. He served as a Senior Staff Fellow of the center for Biologics Evaluation and Research, a division of the FDA, where he was actively involved in regulatory review of cancer and inflammatory disease drugs from 1987 to 1990. He served as Member of the Board of Directors at CGI Pharmaceuticals, Inc. since September 2000. The author of more than 120 scientific papers in the fields of immunology, cell and molecular biology and clinical medicine, Dr. Matis is a recipient of the NIH Award of Merit, the Commendable Service Award from the FDA and was elected to membership in the American Society for Clinical Investigation. He received his B.A., Summa Cum Laude, from Amherst College and his M.D. from the University of Pennsylvania Medical School, where he was elected to Alpha Omega Alpha. He completed his clinical training at the University of Chicago Hospitals and at the NIH and received national board certification in both Internal Medicine and Medical Oncology at the NCI.

Dr. Allan Reine, M.D. has been Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals, Inc. since August 09, 2017. Dr. Reine served as Equity Analyst at CIBC World Markets Corp., American Research Division and CIBC World Markets Inc., Research Division. Prior to joining Pieris, from 2012 through August 2017, he was a portfolio manager at Lombard Odier Asset Management, where he ran a healthcare portfolio focused on biotechnology and pharmaceutical companies. Before joining Lombard Odier, he served as a healthcare portfolio manager at various funds, from 2003 through 2012 including Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management. He began his career in 2001 at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research. Dr. Reine holds M.D. from the University of Toronto and Bachelor of Science in Statistical Sciences from the University of Western Ontario.

Mr. Claus Schalper, MBA served as Vice President of Finance at Pieris Pharmaceuticals, Inc until August 15, 2017. Mr. Schalper co-founded Pieris Pharmaceuticals, Inc. in 2001 and served as its Chief Executive Officer until January 4, 2010. He has been Senior Advisor of Pieris Pharmaceuticals, Inc. since August 22, 2017. He has a solid background in financial management, combined with practical experience in fund raising and driving business growth. Mr. Schalper began his career with Arthur Andersen in the Audit and Corporate Finance Department. Subsequently, he joined a start-up company in the area of healthcare IT software as general partner. Following the trade-sale of the company, Mr. Schalper served as an advisor to venture capitalists specializing in seed financing and as Head of Controlling at Wire Card AG. Mr. Schalper holds a Masters degree in Business Administration from the University of Bamberg, Germany.

Allan Reine serves as the Chief Financial Officer of Pieris Pharmaceuticals. Allan started at Pieris Pharmaceuticals in Aug of 2017. Allan currently resides in the Greater New York City Area.

Ahmed Mousa serves as the Vice President, General Counsel & Corporate Secretary of Pieris Pharmaceuticals. Ahmed started at Pieris Pharmaceuticals in August of 2018. Ahmed currently resides in the Greater Boston Area.

Steve Prelack serves as the Director of Pieris Pharmaceuticals. Steve started at Pieris Pharmaceuticals in January of 2015. Steve currently resides in the Charleston, South Carolina Area.